SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is trending as traders assess its AI dominance amid competition, potential China trade risks, and recent product developments. Community members are actively discussing chart patterns, potential breakouts, and whether the stock remains a top AI play. Sentiment is mixed, with some highlighting new partnerships while others express concerns about valuation and market saturation.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSIT is surging due to a published paper highlighting its APU's comparable performance to NVIDIA GPUs with significantly lower energy consumption, sparking community excitement. Traders are discussing the potential for buyouts and disruption in the AI chip market given the impressive energy efficiency. The community is closely watching for continuation and potential short squeezes.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending as the community assesses the impact of a recently revealed lawsuit from GIC, with many dismissing it as old news and accusing short-sellers of manipulation. Bulls are highlighting the company's potential for growth, pointing to strong delivery numbers for ONVO and overall production capacity. Despite some volatility, investors are closely watching for any signs of profitability and a potential rebound.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending due to news of a potential expansion into rare earth mineral production, sparking excitement and speculation about the company's strategic shift. Community discussions revolve around the implications of this move, with some questioning the feasibility and cost-effectiveness of extracting rare earth minerals from iron ore, while others see it as a game-changer for U.S. strategic metals and a potential re-rating of the stock.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors discuss the potential impact of recent investments and a pending BFS release, with community members speculating on who acquired a significant stake in the company. Conversations also highlight the company's strategic positioning amid the US-Australia partnership for rare earth elements and critical minerals, with some seeing the stock as undervalued while others express concern over market manipulation.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending amid anticipation for data from its Phase III HARMONi trial at the World Conference on Lung Cancer, with bullish investors hoping for strong overall survival results for its lung cancer drug, ivonescimab. Community members are actively debating the drug's potential to compete with Keytruda and the implications of regional differences in trial outcomes, while some analysts maintain high price targets.

Aster is a next-generation decentralized exchange offering both Perpetual and Spot trading, designed as a one-stop onchain venue for global crypto traders. It features MEV-free, one-click execution in Simple Mode. Pro Mode adds 24/7 stock perpetuals, Hidden Orders, and grid trading, available across BNB Chain, Ethereum, Solana, and Arbitrum.  Its unique edge lies in the ability to offer liquid-staking tokens (asBNB) or yield-generating stablecoins (USDF) as collateral, unlocking unparalleled capital efficiency. Powered by Aster Chain, a high-performance and privacy-focused L1, and backed by YZi Labs, Aster is building the future of DeFi: fast, flexible, and community-first.  At the heart of this ecosystem is the $ASTER token, a core asset that decentralizes governance, drives growth, rewards participation, and supports long-term sustainability.

ASTERION

ASTERION ($ASTER) is seeing heightened interest, with community members actively discussing its recent performance and potential catalysts like Robinhood listing rumors. Technical analysis suggests possible bullish patterns, though some traders caution against potential pullbacks and volatility. The coin's connection to Binance and CZ is a recurring theme, with mentions of both positive endorsements and concerns about market manipulation.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon is trending due to a widespread AWS outage impacting major websites and services, sparking discussions about the company's critical role in internet infrastructure and potential fallout.  The community is debating the outage's impact on earnings and whether it exposes vulnerabilities in centralized cloud services, while some see the quick recovery as a testament to Amazon's resilience.  Despite the negative event, the stock has shown surprising strength, fueling debates about its future trajectory and the importance of AWS to Amazon's overall value.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors assess its potential following analyst upgrades and a broader tech sector rally, with some community members eyeing new all-time highs. Discussions include Google's AI initiatives, cloud growth, and various technical analyses, while others express concerns about valuation and potential pullbacks. Recent news of a cybersecurity issue related to Oracle software is also impacting sentiment.

The Mosaic Co. engages in the production and marketing of concentrated phosphate and potash crop nutrients. It operates through the following segments: Phosphates, Potash, and Mosaic Fertilizantes. The Phosphates segment is involved in the ownership and operation of mines and production facilities which produce concentrated phosphate crop nutrients and phosphate-based animal feed ingredients, and processing plants which produce concentrated phosphate crop nutrients. The Potash segment includes mining, processing, and selling potash. The Mosaic Fertilizantes segment focuses on mines, chemical plants, crop nutrient blending and bagging facilities, port terminals, and warehouses. The company was founded on March 25, 2004 and is headquartered in Tampa, FL.

Mosaic Company

Mosaic is trending as investors discuss its valuation and potential catalysts, including production cuts from competitors and the impact of geopolitical events. The community is weighing the company's recent performance against its long-term potential in the fertilizer market, particularly as a value play. Some are speculating on a potential takeover given its low valuation compared to its book value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Apogee Therapeutics Inc. (APGE) Have the Potential to Rally 72.52% as Wall Street Analysts Expect?

The consensus price target hints at a 72.5% upside potential for Apogee Therapeutics Inc. (APGE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

U.S. equities declined in Thursday afternoon trade as Wall Street took a breather following a record-setting rally. The S&amp;P 500 and the Nasdaq Composite indexes both climbed to record highs on Thursday, before paring the gains and declining to trade in the red at the time of writing.Meanwhile, silver prices&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/silver-spot-price-50-first-time-4-decades/ch67qedR3K8">continued to climb</a> on Thursday. Spot silver prices climbed to a new high of $51.38 per troy ounce, rising more than 5% before paring most of the gains.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.41% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, fell 0.45%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.52%.Here are the top stocks making the biggest moves in Thursday’s afternoon trade:<a href="https://stocktwits.com/symbol/DAL">Delta Air Lines Inc. (DAL)</a>Delta shares soared over 5% in Thursday’s afternoon trade after the airline’s third-quarter (Q3) results beat Wall Street expectations. Delta reported earnings per share (EPS) of $1.71 on revenue of $16.67 billion, beating analyst estimates of an EPS of $1.53 on revenue of $15.08 billion, according to Stocktwits data.<a href="https://stocktwits.com/symbol/DAL">DAL stock</a> is down 1% year-to-date.<a href="https://stocktwits.com/symbol/TLRY">Tilray Brands Inc. (TLRY)</a>Tilray Brands shares were up more than 23% in Thursday’s afternoon session after the company’s first-quarter (Q1)&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tilray-brands-stock-skyrockets-on-swing-to-profit-significant-debt-reduction/ch67ouWR3Kj">results</a> came in better than expectations. Tilray reported nil earnings per share (EPS) on revenue of $209.5 million, beating analyst estimates of a loss of $0.03 per share on revenue of $204.55 million, according to Stocktwits data.<a href="https://stocktwits.com/symbol/TLRY">TLRY stock</a> is up 59% year-to-date.<a href="https://stocktwits.com/symbol/PATH">UiPath Inc. (PATH)</a>UiPath shares climbed 15% in Thursday’s afternoon trade, building on the gains over the past few trading sessions following the announcement of collaboration with OpenAI on enterprise agentic automation. The stock surged over 5% on Wednesday and hit new 2025&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ui-path-rises-extended-hours-after-hitting-new-2025-highs/ch67O1jR30f">highs</a> on AI momentum.<a href="https://stocktwits.com/symbol/PATH">PATH stock</a> is up 41% year-to-date.<a href="https://stocktwits.com/symbol/AKRO">Akero Therapeutics Inc. (AKRO)</a>Akero Therapeutics shares were up more than 16% on Thursday after the company announced that it had&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/akero-shares-rally-pre-market-after-announcing-acquisition-by-novo-nordisk/ch67VXUR3K7">entered</a> into a definitive agreement to be acquired by Novo Nordisk AS (NVO) for up to $5.2 billion in cash.<a href="https://stocktwits.com/symbol/AKRO">AKRO stock</a> is up 95% year-to-date.<a href="https://stocktwits.com/symbol/APGE">Apogee Therapeutics Inc. (APGE)</a>Apogee Therapeutics shares continued to gain on Thursday, rising more than 7% after surging 19% on Wednesday. The clinical-stage biotechnology company announced the pricing of a $300 million public offering at $41 per share.<a href="https://stocktwits.com/symbol/APGE">APGE stock</a> is up 12% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/silver-spot-price-50-first-time-4-decades/ch67qedR3K8">Silver Prices Hit $50 For First Time In Over 4 Decades</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Delta Air Lines, Tilray Brands, UiPath, Akero Therapeutics, Apogee Therapeutics: Stocks Making The Biggest Moves Today

Delta shares soared over 5% in Thursday’s afternoon trade after the airline’s third-quarter results beat Wall Street expectations.

Equity

Wall Street Analysts See a 152.41% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 152.4% in Apogee Therapeutics Inc. (APGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See a 129.09% Upside in Apogee Therapeutics Inc. (APGE): Can the Stock Really Move This High?

Wall Street Analysts Think Apogee Therapeutics Inc. (APGE) Could Surge 132.72%: Read This Before Placing a Bet

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...

Apogee (APGE) Stock Rallies 95.6% in a Month: Here's Why

Apogee Therapeutics Inc. APGE, a clinical-stage company, is focused on developing novel therapies for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease...

Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4R  Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases

Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to...

Apogee Therapeutics (NASDAQ:APGE) Stock Price Up 6%

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) rose 6% during trading on Friday . The company traded as high as $71.75 and last traded at $70.50. Approximately 222,641 shares traded...

Apogee Therapeutics, Inc. (NASDAQ:APGE) Given Average Rating of "Buy" by Analysts

Apogee Therapeutics, Inc. (NASDAQ:APGE  Get Free Report) has been given a consensus recommendation of Buy by the seven ratings firms that are presently covering the firm...

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in 2022 and is headquartered in Waltham, MA.

Apogee Therapeutics Inc.

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

APGE
Apogee Therapeutics

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest APGE News

APGEApogee Therapeutics